# Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

> **NCT00858403** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 7 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00858403
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2014-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00858403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00858403, "Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00858403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*